GX 051

Drug Profile

GX 051

Alternative Names: GX-051; GX-51

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genexine
  • Class Cancer vaccines; Cell therapies; Gene therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inhibitors; CD8 positive T lymphocyte stimulants; Immunostimulants; Interferon gamma stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Head and neck cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Late-stage disease) in South Korea (Intratumoural, Injection)
  • 01 Mar 2014 Phase-I clinical trials in Head and neck cancer (late-stage disease) in South Korea (Intratumoural) (NCT02079324)
  • 27 Feb 2014 Genexine plans a phase I trial for Heck and neck cancer (late-stage disease) in South Korea (NCT02079324)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top